Literature DB >> 8512095

Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients.

G F Rich1, G D Murphy, C M Roos, R A Johns.   

Abstract

BACKGROUND: Inhaled nitric oxide (NO), an endothelium-derived relaxing factor, is a selective pulmonary vasodilator. The authors investigated whether the pulmonary vasodilation resulting from 20 ppm inhaled NO is related to the degree of pulmonary hypertension or affected by cardiopulmonary bypass (CPB) or the presence of intravenous nitrates.
METHODS: In patients undergoing cardiac surgery (n = 20) or in whom the circulation was supported with a ventricular assist device (VAD; n = 5), the lungs were ventilated with 80% O2 and 20% N2 followed by the same gas concentrations containing 20 ppm NO for 6 min.
RESULTS: Inhaled NO decreased (P < 0.05) the pulmonary artery pressure from 36 +/- 3 to 29 +/- 2 mmHg and 32 +/- 2 to 27 +/- 1 mmHg, before and after CPB, respectively, and from 68 +/- 12 to 55 +/- 9 mmHg in patients with a VAD. Similarly, the pulmonary vascular resistance (PVR) decreased (P < 0.05) from 387 +/- 44 to 253 +/- 26 dyne.cm.s-5 and 260 +/- 27 to 182 +/- 18 dyne.cm.s-5, before and after CPB, respectively, and from 1,085 +/- 229 to 752 +/- 130 dyne.cm.s-5 in patients with a VAD. Central venous pressure, cardiac output, systemic hemodynamics, and blood gases did not change after inhalation of NO before or after CPB, whereas arterial oxygen tension, mixed venous hemoglobin saturation, and mean arterial pressure increased (P < 0.05) in patients supported with a VAD. All hemodynamic and laboratory data returned to control 6 min after discontinuation of NO. The decrease in PVR was proportional to baseline PVR (delta PVR = -0.45 PVRb + 39.9) before CPB. The pre- and post-CPB slopes were identical despite possible damage to the endothelium resulting from CPB and the post-CPB presence of intravenous nitroglycerin (17 of 20 patients).
CONCLUSIONS: This study demonstrates that 20 ppm inhaled NO is a selective pulmonary vasodilator in cardiac surgical patients before and after CPB and in patients in whom the circulation is supported with a VAD. Furthermore, NO-induced pulmonary vasodilation is proportional to PVRb and does not appear to be altered by CPB, the presence of a VAD, or infusion of nitrates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512095

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

2.  Inhaled nitric oxide delivery and monitoring.

Authors:  F J Montgomery; A D Berssenbrugge
Journal:  J Clin Monit Comput       Date:  1999-07       Impact factor: 2.502

Review 3.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

4.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 5.  Delivery and monitoring of inhaled nitric oxide.

Authors:  J D Young; O J Dyar
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

6.  UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS.

Authors:  B H Cuthbertson; P Dellinger; O J Dyar; T E Evans; T Higenbottam; R Latimer; D Payen; S A Stott; N R Webster; J D Young
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

Review 7.  Management of pulmonary hypertension and right heart failure in the intensive care unit.

Authors:  Jonathan Grinstein; Mardi Gomberg-Maitland
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

8.  Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Authors:  Edward A Pankey; Adeleke M Badejo; David B Casey; George F Lasker; Russel A Riehl; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Nitric Oxide       Date:  2012-03-14       Impact factor: 4.427

9.  Inhaled nitric oxide for hemodynamic support after postpneumonectomy ARDS.

Authors:  J D Chiche; J L Canivet; P Damas; J Joris; M Lamy
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

Review 10.  Inhaled nitric oxide.

Authors:  R G Pearl
Journal:  West J Med       Date:  1995-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.